MEK Inhibition Aids in Serous Ovarian Cancer

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 05期
关键词：
D O I：
10.1158/2159-8290.CD-NB2012-029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a phase II trial of the experimental MEK inhibitor selumetinib (AZD6244), women who had failed 3 or more rounds of chemotherapy had 81% disease control and a median progression-free survival of 11.3 months.
引用
收藏
页数：2
相关论文
共 50 条
  • [21] KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
    N Nakayama
    K Nakayama
    S Yeasmin
    M Ishibashi
    A Katagiri
    K Iida
    M Fukumoto
    K Miyazaki
    British Journal of Cancer, 2008, 99 : 2020 - 2028
  • [22] KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
    Nakayama, N.
    Nakayama, K.
    Yeasmin, S.
    Ishibashi, M.
    Katagiri, A.
    Iida, K.
    Fukumoto, M.
    Miyazaki, K.
    BRITISH JOURNAL OF CANCER, 2008, 99 (12) : 2020 - 2028
  • [23] Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
    Marta Llaurado Fernandez
    Amy Dawson
    Joshua Hoenisch
    Hannah Kim
    Sylvia Bamford
    Clara Salamanca
    Gabriel DiMattia
    Trevor Shepherd
    Mattia Cremona
    Bryan Hennessy
    Shawn Anderson
    Stanislav Volik
    Colin C. Collins
    David G. Huntsman
    Mark S. Carey
    Cancer Cell International, 19
  • [24] BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
    Campos, Maira P.
    Cohen, Melissa
    Von Euw, Erika
    Velculescu, Victor
    Kujak, Jennifer L.
    Conklin, Dylan
    Hallberg, Dorothy
    Slamon, Dennis J.
    Elvin, Julia
    Konecny, Gottfried E.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 6
  • [25] Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
    Fernandez, Marta Llaurado
    Dawson, Amy
    Hoenisch, Joshua
    Kim, Hannah
    Bamford, Sylvia
    Salamanca, Clara
    DiMattia, Gabriel
    Shepherd, Trevor
    Cremona, Mattia
    Hennessy, Bryan
    Anderson, Shawn
    Volik, Stanislav
    Collins, Colin C.
    Huntsman, David G.
    Carey, Mark S.
    CANCER CELL INTERNATIONAL, 2019, 19 (1)
  • [26] Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
    Fernandez, Marta Llaurado
    DiMattia, Gabriel E.
    Dawson, Amy
    Bamford, Sylvia
    Anderson, Shawn
    Hennessy, Bryan T.
    Anglesio, Michael S.
    Shepherd, Trevor G.
    Salamanca, Clara
    Hoenisch, Josh
    Tinker, Anna
    Huntsman, David G.
    Carey, Mark S.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (10): : 2235 - 2251
  • [27] Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model
    McCann, Christopher K.
    Growdon, Whitfield B.
    Kulkarni-Datar, Kashmira
    Curley, Michael D.
    Friel, Anne M.
    Proctor, Jennifer L.
    Sheikh, Hana
    Deyneko, Igor
    Ferguson, Jeanne A.
    Vathipadiekal, Vinod
    Birrer, Michael J.
    Borger, Darrell R.
    Mohapatra, Gayatry
    Zukerberg, Lawrence R.
    Foster, Rosemary
    MacDougall, John R.
    Rueda, Bo R.
    PLOS ONE, 2011, 6 (11):
  • [28] BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition
    Moujaber, Tania
    Etemadmoghadam, Dariush
    Kennedy, Catherine J.
    Chiew, Yoke-Eng
    Balleine, Rosemary L.
    Saunders, Catherine
    Wain, Gerard, V
    Gao, Bo
    Hogg, Russell
    Srirangan, Sivatharsny
    Kan, Casina
    Fereday, Sian
    Traficante, Nadia
    Patch, Ann-Marie
    Pearson, John, V
    Waddell, Nicola
    Grimmond, Sean M.
    Dobrovic, Alexander
    Bowtell, David D. L.
    Harnett, Paul R.
    DeFazio, Anna
    Bowtell, D.
    Chenevix-Trench, G.
    Green, A.
    Webb, P.
    DeFazio, A.
    Gertig, D.
    Traficante, N.
    Fereday, S.
    Moore, S.
    Harrap, K.
    Sadkowsky, T.
    Pandeya, N.
    Hung, J.
    Malt, M.
    Alexander, B.
    Ashover, E.
    Brown, S.
    Corrish, T.
    Green, L.
    Jackman, L.
    Ferguson, K.
    Martin, K.
    Martyn, A.
    Ranieri, B.
    Mellon, A.
    Robertson, R.
    Vanden Bergh, T.
    Jones, M.
    Mackenzie, P.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 14
  • [29] Preclinical efficacy of combined MEK and Src inhibition: MEK inhibitor reverses resistance to Src inhibitor therapy in ovarian cancer cells
    Simpkins, Fiona
    Azzam, Diana
    Slingerland, Joyce M.
    CLINICAL CANCER RESEARCH, 2013, 19
  • [30] CD 56 expression in serous invasive ovarian cancer and serous ovarian borderline tumors
    Pokieser, W.
    Hauptmann, S.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 151 - 151
12345